

Variation of the Net Charge, Lipophilicity, and Side Chain Flexibility in Dmt¹-DALDA: Effect on Opioid Activity and Biodistribution

Alexandre Novoa,[†] Sylvia Van Dorpe,[‡] Evelien Wynendaele,[‡] Mariana Spetea,[§] Nathalie Bracke,[‡] Sofie Stalmans,[‡] Cecilia Betti,[†] Nga N. Chung,^{||} Carole Lemieux,^{||} Johannes Zuegg,[⊥] Matthew A. Cooper,[⊥] Dirk Tourwé,[†] Bart De Spiegeleer,^{*,‡} Peter W. Schiller,^{||} and Steven Ballet^{*,†}

[†]Department of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium

[‡]Drug Quality and Registration (DruQuaR) Group, Department of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium


[§]Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria

^{||}Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, QC, Canada

[⊥]Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia

Supporting Information

ABSTRACT: The influence of the side chain charges of the second and fourth amino acid residues in the peptidic μ opioid lead agonist Dmt-D-Arg-Phe-Lys-NH₂ ([Dmt¹]-DALDA) was examined. Additionally, to increase the overall lipophilicity of [Dmt¹]-DALDA and to investigate the Phe³ side chain flexibility, the final amide bond was *N*-methylated and Phe³ was replaced by a constrained aminobenzazepine analogue. The *in vitro* receptor binding and activity of the peptides, as well as their *in vivo* transport (brain in- and efflux and tissue biodistribution) and antinociceptive properties after peripheral administration (ip and sc) in mice were determined. The structural modifications result in significant shifts of receptor binding, activity, and transport properties. Strikingly, while [Dmt¹]-DALDA and its *N*-methyl analogue, Dmt-D-Arg-Phe-NMeLys-NH₂, showed a long-lasting antinociceptive effect (>7 h), the peptides with D-Cit² generate potent antinociception more rapidly (maximal effect at 1h postinjection) but also lose their analgesic activity faster when compared to [Dmt¹]-DALDA and [Dmt¹,NMeLys⁴]-DALDA.



INTRODUCTION

Due to the present limitations of the pharmacotherapy of pain, the development of novel medications for the treatment of severe and chronic pain represents a high priority goal. To date, these pathologies rely mostly on opioid analgesics, but the current available opioid drugs produce a number of side-effects that limit their clinical use. A considerable amount of work has been done and is still needed to target more efficacious and nonaddicting analgesics in order to solve this major health care problem. One research avenue consists of the discovery and development of a potent peptide-based analgesic, with reduced undesired effects, requiring a compound with a high affinity for μ and/or δ opioid receptors (MOR and DOR, respectively), a potent *in vitro* agonist activity, a strong antinociceptive effect *in vivo*, an improved resistance to enzymatic degradation, and the ability to cross the blood–brain barrier (BBB), allowing systemic administration. More specifically, it was evidenced that compounds with a dual MOR/DOR activity present beneficial pharmacological effects in comparison to highly selective MOR agonists. There have been reports on synergistic

effects between MOR agonists and DOR agonists.^{1,2} Therefore, compounds with a mixed μ agonist/ δ agonist profile have the potential to be effective for the treatment of pain with reduced side effects, as lower doses would be required.³ In parallel to the development of such dual agonists, mixed MOR agonists/DOR antagonists were also designed in search of a better pain management.^{4–6} Among other beneficial effects, the observation that the selective blockade of DOR suppressed morphine tolerance and dependence motivated the development of compounds with this mixed profile.⁷

Earlier studies, performed by Schiller and co-workers,⁸ on the dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂)-derived tetrapeptide H-Dmt-D-Arg-Phe-Lys-NH₂ (**1**) ([Dmt¹]-DALDA, Figure 1), identified this peptide as a highly potent MOR agonist with a high binding affinity at the MOR ($K_i^\mu = 0.143$ nM, 7-fold higher than morphine) and a high metabolic stability when incubated in sheep blood ($t_{1/2} = 1.8$ h).⁹ The C-

Received: June 8, 2012

Published: October 29, 2012





Figure 1. Structures of Dmt-DALDA (**1**), Phe, and the conformationally constrained 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba)-containing dipeptide **2** (with Xxx: an α -amino acid residue).

Scheme 1. Synthesis of Fmoc-Aba-Lys(Z)-OH **8a and Fmoc-Aba-Nle-OH **8b** Dipeptide Mimetics^a**



^aReaction conditions: (a) H₂ (50 psi), RaNi, H₂O/AcOH/Py 1:1:1, 50 °C, 38 h, 78%; (b) 1.1 equiv HCl·H-Lys(Z)-OMe or HCl·H-Nle-OMe, 2.5 equiv NaCNBH₃, 20 wt % MgSO₄, CH₂Cl₂, NMM or AcOH, rt, 14 h; (c) 1.1 equiv DCC, Py, CH₃CN/H₂O 1:1, rt, 14 h; (d) acetone/HCl 1N 1:1, rt, reflux, 16 h; (e) (i) 4 equiv NH₂NH₂·H₂O, EtOH, reflux, 1.5 h, and (ii) 1.2 equiv Fmoc-OSu, 2.2 equiv NaHCO₃, acetone/water 1:2, rt, 2 h.

terminal amidation and insertion of a D-Arg residue in position 2 are likely to assist in the high stability of this peptide.⁹ Moreover, [Dmt¹]DALDA showed extraordinary potency in the rat tail-flick assay after intrathecal administration (3000 times more potent than morphine),¹⁰ and a subcutaneous (sc) administration also induced a potent analgesic response,^{11,12} which in turn indicated that this molecule is able to cross the BBB. Nevertheless, the structural features of this tricharged peptide responsible for its ability to cross the BBB have not clearly been determined.

The introduction of a conformational constraint and the *N*-methylation of peptidic amide bonds are well-known procedures to improve the stability and the activity of (opioid) peptides.^{13,14} Previously, we have used the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold **2** (Figure 1) as a tool for introducing a local conformational constraint in opioid peptides.^{15–19} The synthetic Aba residue can be considered as a constrained phenylalanine where the phenyl group is fixed to the amine of the next amino acid via a methylene bridge.¹⁷ Previous work on opioid peptides indicated that replacement of Phe by Aba in dermorphin-based sequences improves the DOR affinity considerably, while preserving the binding to the MOR.^{17,18} Additionally, peptides containing this constraint represent highly active antinociceptive agents when tested in vivo, as recently reported.¹⁹ Similarly, amide *N*-methylation in opioid peptide sequences have shown to result in retained opioid receptor binding and activation,²⁰ as well as improved BBB passage²¹ when compared to the nonmethylated analogues. Therefore, both conformational side chain re-

striction and *N*-methylation prove to be efficient techniques in improving the pharmacokinetic and pharmacodynamic profile of dual MOR/DOR opioid peptides.²²

The present work describes the chemical modification of the MOR lead tetrapeptide [Dmt¹]DALDA (Figure 1). The different modifications that were carried out comprise: (i) changing the overall net charge in the peptide by replacing the D-Arg² residue by a D-Cit² and/or the Lys⁴ residue by a Nle⁴, (ii) the introduction of a *N*-methyl group in the amide bond connecting residues in position 3 and 4 in order to protect the peptide against enzymatic degradation and to increase the overall lipophilicity of the peptide, and (iii) introducing a conformational constraint by means of an Aba³ residue that replaces Phe³ in the Dmt¹[DALDA] sequence. The synthesized peptides have been investigated for their opioid receptor binding affinity and agonist potency, BBB permeability, plasma stability, and antinociceptive activities. Structure–activity relationship (SAR) studies relating to the substitution pattern in targeted positions within this series were pursued.

RESULTS AND DISCUSSION

Synthesis. All standard and *N*-methylated amino acids were obtained from commercial sources, whereas the conformationally constrained aminobenzazepinones of type **2** were prepared as described below and used in standard solid phase peptide synthesis.

1. Synthesis of the 4-Amino-2-benzazepin-3-one Scaffolds. The preparation of the required Aba-Lys/Nle dipeptidomimetics **8a,b** was performed using a previously reported²³

Table 1. Structures, Receptor MOR/DOR Binding Affinities and in Vitro Potency Data

structure	compd	MOR K_i (nM) ^a	DOR K_i (nM) ^a	KOR K_i (nM)	K_i ratio $\mu/\delta/\kappa$	GPI (μ) IC ₅₀ (nM) ^a	MVD (δ) IC ₅₀ (nM) ^a
H-Dmt-D-Arg-Phe-Lys-NH ₂ ^b	1	0.143	2100	22.3	1/11400/156	1.41	23.1
H-Dmt-D-Arg-Phe-Nle-NH ₂	9	0.23	15.2	16.2	1/66/70	2.2	6.2
H-Dmt-D-Cit-Phe-Lys-NH ₂	10	0.57	50.0	20.9	1/88/37	0.31	1.4
H-Dmt-D-Cit-Phe-Nle-NH ₂	11	0.79	3.98	98.5	1/5/125	0.89	4.7
H-Dmt-D-Arg-Phe-NMeLys-NH ₂	12	0.26	309	56.1	1/1190/216	8.3	7.0
H-Dmt-D-Arg-Phe-NMeNle-NH ₂	13	0.26	16.0	14.4	1/62/55	4.35	1.5
H-Dmt-D-Cit-Phe-NMeLys-NH ₂	14	0.94	39.2	11.5	1/42/12	1.01	4.4
H-Dmt-D-Cit-Phe-NMeNle-NH ₂	15	2.92	5.03	>10.000	1/2/>3420	0.65	1.5
H-Dmt-D-Arg-Aba-Lys-NH ₂	16	0.61	38.6	ND	1/64/–	76.0	64 (IC ₂₅)
H-Dmt-D-Arg-Aba-Nle-NH ₂	17	0.43	7.46	1.12	1/17/3	1.45	3.1
H-Dmt-D-Cit-Aba-Lys-NH ₂	18	2.62	56.9	ND	1/22/–	49.0	1000
H-Dmt-D-Cit-Aba-Nle-NH ₂	19	0.93	3.18	11.1	1/3/12	0.78 (IC ₃₅)	1.16
H-Dmt-D-Arg-Aba-Gly-NH ₂ ^c	20	0.15	0.60	118	1/4/787	0.32	0.42

^aValues represent means of 3–6 experiments. The GPI functional assay is representative of MOR activation, whereas the MVD is a DOR receptor-representative assay. Binding affinities of compounds for MOR and DOR opioid receptors were determined by displacement of [³H]DAMGO ([D-Ala²,NMePhe⁴,Gly-ol⁵]enkephalin) and [³H]DSLET ([D-Ser²,Leu⁵]enkephalin-Thr⁶) from rat brain membrane binding sites, respectively. KOR receptor binding affinities were determined by displacement of [³H]U69,593 from guinea pig ileum membrane binding sites. ^bData taken from ref 8. ^cData taken from ref 15.

and optimized procedure²⁴ (Scheme 1). The phthaloyl-protected (*S*)-*o*-cyano-phenylalanine **3** was obtained by reaction of methyl 2-[(succinimidooxy)-carbonyl]benzoate²⁵ with the commercially available *o*-(*S*)-cyanophenylalanine. The corresponding *o*-formyl intermediate **4** was formed by hydrogenation with Raney nickel in an acetic acid/water/pyridine mixture. Reductive amination of **4** with lysine and norleucine amino acid methyl esters resulted in secondary amines **5a/b**, which were subsequently used for the dicyclohexylcarbodiimide-induced ring closure to present the desired amino-benzazepinones **6a/b**. Ester hydrolysis, followed by phthaloyl-removal with hydrazine hydrate and final Fmoc-protection, gave the required Fmoc-Aba-Lys(Z)/Nle-OH building blocks **8a/b**, which were used in the peptide synthesis.

2. Peptide Synthesis. The peptides in this study were synthesized manually using *N*^α-Fmoc- or *N*^α-Boc-protected amino acids on Rink amide resin (0.31 mmol scale) and MBHA resin (0.29 mmol scale) using DIC and 1-hydroxybenzotriazole (HOBt) or *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU)/*N,N*-diisopropylethylamine (DIPEA) as the coupling reagents/mixtures. A 3-fold excess of the building blocks (Fmoc-Aba-Lys(Z)-OH, Fmoc-Aba-Nle-OH, Fmoc-Lys(Boc)-OH, Boc-Lys(Z)-OH, Boc-NMeLys(Z)-OH, Fmoc-Nle-OH, Boc-NMeNle-OH, Fmoc- or Boc-Phe-OH, Fmoc-D-Arg(Pbf)-OH, Boc-D-Arg(Tos)-OH, Boc-D-Cit-OH, and Boc-Dmt-OH) and activating agents was applied, and dry DMF was used as a solvent. Fmoc deprotections were carried out by treating the resin twice (5 and 15 min) with 20% piperidine in DMF. Boc-Dmt-OH was used in a final coupling to directly present the fully unprotected peptide after acidic cleavage from the resin. Boc-Dmt-OH was coupled with 1,3-diisopropylcarbodiimide (DIC) and HOBt in order to avoid side reactions when uronium-based coupling reagents were used. Final cleavage of the peptide as well as the 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) side chain protection group removal was accomplished by treatment with TFA/CH₂Cl₂/anisole 90:5:5 for 90 min (Rink resin) or standard HF/anisole cleavage conditions for 60 min (MBHA resin). The crude peptides were obtained after evaporation of the cleavage mixture, precipitation in cold Et₂O, dissolving in glacial acetic acid, and subsequent lyophilization. Final


purification was performed by RP-HPLC on a SUPELCO DiscoveryBIO wide pore preparative C18 column in 45% overall yield and was >95% pure as determined by analytical RP-HPLC. The structures of the compounds were confirmed by high-resolution electrospray (ESP) ionization mass-spectrometry.

Biological Evaluation and Structure–Activity Relationships. *In Vitro Opioid Receptor Binding and Activity* (Table 1). The investigated peptides can be subdivided in three series: (i) peptides **1** and **9–11** in which the side chain charges were altered, (ii) the analogous series where the α -amine of the C-terminal residue is methylated (peptides **12–15**), and (iii) the tetrapeptides with restricted side chain flexibility after a Phe³→Aba³ substitution (compounds **16–19**). Peptide **20** (Dmt-D-Arg-Aba-Gly-NH₂) was reported recently¹⁹ but is included in this work as a reference compound.

In general, the replacement of D-Arg² in the H-Dmt-D-Arg-Phe-Lys-NH₂ analogues by D-Cit² preserves the low- to subnanomolar MOR binding affinity, produces shifts in κ opioid receptor (KOR) binding, and enhances the DOR affinity in most cases (except for **18** vs **16**). This MOR/DOR selectivity shift is in agreement with the in vitro functional activities at both receptor types, as indicated by the results of the guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassays. Structurally, D-Cit resembles D-Arg but it is not charged at physiological pH. The binding and activation of MOR and DOR confirms that the charge of the guanidinium moiety in D-Arg² is not crucial for receptor recognition, being in line with earlier findings of other opioid peptides such as, for example, the dermorphin, endomorphin, and enkephalin peptides that bear respectively a D-Ala, Pro, or Gly residue in position 2. Similarly, the side chain charge of the Lys residue in position 4 was removed via replacement with Nle, a residue that lacks the terminal amino group in the side chain. As shown in Table 1, this modification did not markedly affect the interaction with the MOR receptor but produced a significant 55-fold (**1** vs **9**), 19-fold (**12** vs **13**), and 5-fold (**16** vs **17**) improvement of both DOR binding and in vitro functional activity (4-fold (**1** vs **9**), 5-fold (**12** vs **13**), and 21-fold (**16** (IC₂₅) vs **17**)). In this case, the favorable interaction with DOR may be a result of not only the absence of a side chain charge

Table 2. Blood–Brain Barrier Transport Data of the [125 I]-Peptides (Mean \pm SEM)

peptide	K_{in} initial ($\mu\text{L}/(\text{g} \times \text{min})$)	V_{br} ($\mu\text{L}/\text{g}$)	capillary fraction (%)	parenchyma fraction (%)	k_{out} (min^{-1})
1	9.44 \pm 0.41	19.25 \pm 1.02	23.12 \pm 10.26	76.88 \pm 10.26	0.058 \pm 0.11
9	8.48 \pm 1.61	27.43 \pm 4.80	32.97 \pm 9.99	67.03 \pm 9.99	-0.039 \pm 0.11
10	14.91 \pm 0.10	27.12 \pm 3.76	19.39 \pm 15.81	80.61 \pm 15.81	0.027 \pm 0.022
12	18.11 \pm 0.78	21.99 \pm 2.81	25.95 \pm 0.95	74.05 \pm 0.95	0.028 \pm 0.030
14	11.35 \pm 0.61	17.13 \pm 2.36	21.84 \pm 1.32	78.16 \pm 1.32	0.010 \pm 0.038
20	14.89 \pm 1.34	24.01 \pm 3.41	30.95 \pm 19.75	69.05 \pm 19.75	0.096 \pm 0.046

Figure 2. Mean distribution of the [125 I]-peptides into the different tissues.

but also other factors like hydrogen bonding or steric effects (amine function vs hydrogen) have to be considered. In respect to the KOR affinity, the Lys⁴→Nle⁴ substitution slightly improves binding when D-Arg² is preserved (1 vs 9 and 12 vs 13). However, when combined with the D-Arg²→D-Cit² modification, a significant loss of KOR affinity is observed.

Previously, we have shown that constraining the conformation of Phe³ in dermorphin-derived tetrapeptides into a 4-amino-tetrahydro-2-benzazepin-3-one ring 2 leads to highly potent peptides.^{18,19} To distinguish the influence of the ring constraint from that of the *N*-alkylation of the Gly⁴ residue, the “ring opened” analogues containing an amide *N*-methylation were prepared and were shown to be of equal potency.²¹ Therefore, the *N*-methylated Lys⁴ analogues of Dmt¹-DALDA were then also investigated. The *N*-methylation of the Xxx³-Yyy⁴ amide bond, on the other hand, influences the *cis*-*trans* isomer equilibrium of the peptide bond between these amino acids and stabilizes this bond against enzymatic degradation but also increases the overall lipophilicity of the peptide analogues. Clearly, when comparing the peptides of the first series (peptides 1 and 9–11) with the respective peptide analogues of the second series (12–15), the receptor binding data were very similar, whereas the functional GPI and MVD assays gave values slightly in disfavor of MOR activation but in favor of DOR activity.

In contrast to the first eight analogues in Table 1, for which high MOR and DOR receptor binding and potent opioid

activity are obtained, the next analogues including the conformationally constrained Aba-Lys dipeptide (16 and 17) presented in vitro activity data with more pronounced shifts. When Aba³-Lys⁴ was inserted in the peptide (16), the MOR affinity was retained, but the DOR affinity increased by a factor of 23, in agreement with previous findings.¹⁸ However, the ability to activate MOR and DOR decreased substantially. Because of this drop in activity, we did not perform any further KOR binding studies for compounds 16 and 18. The ability of DOR activation was restored in the Nle⁴ analogue 17 and concomitantly improved KOR binding considerably (IC₅₀^K 1.12 nM). A combination of D-Cit² and Aba³-Nle⁴ substitutions in 19 resulted in the conversion of the potent MOR selective Dmt¹-DALDA 1 into a potent nonselective MOR partial agonist/DOR full agonist 19.

Previously, the opioid sequence Dmt¹-D-Arg²-Aba³-Gly⁴-NH₂, 20 was identified as a potent antinociceptive opioid peptide.¹⁵ The present data showed that the constrained amino-azepinone scaffold should not be used in opioid tetrapeptides in combination with a Lys⁴ amino acid but preferably in combination with a Gly⁴ residue when aiming at combined MOR/DOR agonists.

Brain Influx and Efflux. Determination of the blood–brain barrier transport properties (initial influx K_{in} , V_{br} , brain capillary and parenchyma fraction, and efflux k_{out}) form important parameters to determine the “druggability” of central nervous system (CNS) compounds. Therefore, the transport properties

of the peptides **1**, **9**, **10**, **12**, **14**, and **20** were determined in CD-1 mice. After labeling with ^{125}I , the radiolabeled peptides were injected into the jugular vein, and at specified time points after injection, the mice were decapitated and the brain was isolated for analysis (Table 2). These data clearly indicate an influx into the mouse brain for all peptides: peptides **12**, **10**, **20**, and **14** show the highest initial K_{in} values, indicating a rapid and high influx of the radiolabeled peptides into the brain, while peptides **9** and **1** demonstrate slower influx properties. Moreover, the apparent brain distribution volumes, obtained from 15 min time interval and calculated according to Gjedde,²⁶ indicate relative high values of 27 $\mu\text{L}/\text{g}$, compared to 15 $\mu\text{L}/\text{g}$ for the negative control bovine serum albumin (BSA). On the basis of the capillary depletion results, a higher parenchyma versus capillary distribution for all peptides is observed: the amount of peptide entering the brain is mostly transferred from the capillaries to the parenchyma. This is in accordance with previous distribution results of other opioid peptides.²⁷ However, despite the good brain influx properties of peptide **20**, the net effect is expected to be reduced due to the significant brain to blood efflux transport. Also peptide **1** shows a non-negligible efflux, while this is less observed for peptides **10** and **12** and not at all for peptides **9** and **14**.

Additionally, and in an effort to predict and potentially rank the ability of the peptides to permeate the BBB via use of an in vitro test, all compounds were subjected to a Caco-2 permeability assay (Supporting Information). Very low peptide transport values through the Caco-2 cell monolayers (in both directions, i.e., apical \rightarrow basal (A \rightarrow B) and basal \rightarrow apical (B \rightarrow A)) were observed. However, a positive observation that was made from this study consisted of a low B \rightarrow A transport, which is indicative of not hitting p-glycoprotein, an important efflux transporter that is present at high concentration in the luminal membrane of the brain endothelia.

In Vivo Tissue Biodistribution. Immediately after brain dissection, the spleen, liver, lungs, heart, and kidneys were collected, the tissues were weighed, and the amount of radioactivity was measured. For each tissue, the percentage of mass-corrected injected dose (ID) was then calculated as described in the Experimental Section. The tissue distribution plots (Figure 2) show a strikingly high liver accumulation for peptide **9** as a consequence of the Lys⁴ replacement by Nle⁴. Also for peptide **10**, a high liver, as well as kidney extraction, is observed. This higher kidney uptake is also seen for peptides **1** and **20** despite the structural differences between both peptides. The two peptide analogues containing the amide *N*-methyl groups (peptides **12** and **14**) present a more balanced distribution between the different organs. The serum levels observed 15 min after administration were the highest for peptide **1**, the lowest for peptide **9**, and intermediate for peptides **10**, **12**, **14**, and **20**.

In Vitro Metabolic Stability. The in vitro metabolic stability of unlabeled peptides **1** and **9** was determined in mouse plasma and brain homogenate using UPLC RP C18-chromatography, while the other peptides were investigated using the Prevail organic acid column (HPLC). All peptides could undeniably be distinguished from tissue components, resulting in a reliable data evaluation. The peptides were observed to be very stable in mouse plasma and brain homogenate for at least 2 h (Table 3). There is also no adsorption nor chemical degradation observed for the peptides under investigation. The BBB characteristics can thus be assigned to the native peptides. Comparatively, on the contrary, endomorphin-1 and endomorphin-2 for example

Table 3. Peptide Recovery after 2 h of in Vitro Incubation

peptide	mean recovery in plasma (%)	mean recovery in brain (%)
1	94.7	102.6
9	90.2	103.7
10	98.3	96.2
12	112.4	94.0
14	103.9	95.0
20	107.2	99.6

show very poor half-lives in mouse plasma: a $t_{1/2}$ of 4–7 min indicates a rapid enzymatic degradation of these peptides.²⁸

In Vivo Antinociceptive Properties. Given the superior potency of peptides **1** and **10** and the absence of promising in vitro affinity and potency data for the [Aba-Lys]- and [Aba-Nle]-containing peptides (compounds **16**–**19**), only the selected [Dmt¹]DALDA analogues **1**, **9**, **10**, **12**, **14**, and **20** were investigated in vivo for their antinociceptive activity using the tail-flick test in mice after intraperitoneal (ip) and subcutaneous (sc) administration. The antinociception, resulting from ip injection of the compounds, is shown in Figure 3, with morphine as a positive control. All peptides generated an antinociceptive effect significantly different from control mice receiving ip saline. As a reference peptide, the naturally occurring opioid peptide dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) was included in the study.²⁹ Figure 3 illustrates the inability of dermorphin to induce a significant antinociceptive effect at the applied dose after ip injection.

Peptide **9** had a relatively low antinociceptive activity, similar to morphine and dermorphin, at 60 min post ip injection. In contrast, the parent peptide **1** as well as the peptide bearing a D-Cit residue in position 2 (**10**) produced potent responses. Peptide **1** showed a maximum antinociceptive activity at 60 min post ip injection, while the maximum antinociceptive activity of peptide **10** was reached at an earlier time point, i.e., at 45 min. This can be explained by the lower initial K_{in} value together with the high serum concentration observed at 15 min post injection obtained for peptide **1**. Peptide **10** showed good initial brain influx properties, resulting in a relatively rapid onset of antinociception. The D-Arg² \rightarrow D-Cit² substitution changes the polarity of **1** in such a way that brain influx is accelerated (see K_{in} Table 2). The rapid relapse of antinociception, on the other hand, can be explained by the kidney and liver extraction, seen at 15 min post injection. Both peptides gave responses that were superior to the response of peptide **20**. Despite the high initial K_{in} value of peptide **20**, the efflux and kidney uptake characteristics highly influence its analgesic profile, as a slow and shallow antinociceptive response is produced by this peptide. Peptides **12** and **14** showed a rapid increase of antinociception over time, reaching the highest plateau values at 60–90 min post ip injection. During the first 45 min after injection, peptide **12** reached potent antinociception at a slower rate than peptide **14**. After the maximal effect, i.e., at the plateau decline phase, both peptides still showed a high antinociceptive activity (13–15 times higher than the antinociception of morphine). These analgesic profiles can be explained by the high initial brain influx properties (K_{in}) and insignificant outflux rate (k_{out}) of both peptides. Taken together, the relatively high serum concentrations after 15 min ip and the absence of massive tissue extraction provide an explanation for the plateauing characteristics. Finally, the disappointing antinociceptive activity of peptide **9** can be understood by the low




Figure 3. Antinociceptive characteristics of the [Dmt¹]-DALDA analogues after ip administration. (left) Time response curves of the peptides (dose of 1 μmol/kg, *n* = 10). Morphine and dermorphin at a dose of 1 μmol/kg (*n* = 10) were used as positive controls. The error bars represent the standard error of the mean (SEM). All data were saline-corrected. (right) Area under the curve normalized to a dose of 1 μmol/kg based on antinociception measured during 120 min postinjection.

initial K_{in} , indicating a slow onset of antinociception, together with the excessive liver extraction results.

When analyzing the dose-normalized area under the curve values (AUCs, 1 μmol/kg) (Figure 3) of the initial 120 min post injection, we could conclude that peptide 14 (1412%·min) had the highest antinociceptive effect, followed by peptide 12 (1187%·min), peptide 1 (750%·min), peptide 10 (521%·min), and peptide 20 (253%·min). The positive control morphine had a much lower AUC, i.e., 66%·min, similar to peptide 9 (65%·min) and dermorphin (46%·min).

Looking at the structural characteristics of peptides 1–14, it is clear that the C-terminal amino acid is the most determining factor for the antinociceptive activity: the presence of NMeLys (12 and 14) is preferred, followed by Lys (1 and 10), while other amino acids like Nle (9) decreased its antinociceptive activity significantly. The effect of varying Arg and Cit at position 2 is less pronounced but cannot be neglected. It shows a confounding effect with the amino acid on position 4: if this is NMeLys, then Cit² gives a higher activity (14 versus 12), while if position 4 is Lys, the reverse is true and Arg² gives the highest activity (1 versus 10).

In addition to the primary evaluation of antinociceptive properties of peptides 1, 9, 10, 12, 14, and 20 after ip administration, a further *in vivo* study assessing the dose- and time-dependent antinociceptive effects after sc administration was performed using the mouse tail-flick test. Antinociceptive properties of the six peptides, given sc, were compared to those of morphine and are illustrated in Figure 4. The calculated ED₅₀ values with 95% confidence intervals are shown in Table 4. The overall profile of antinociceptive effects after sc administration closely match that determined after ip administration.

Dose-dependent and long duration of action lasting up to 6–7 h was shown by peptides 1 (Figure 4A), 12 (Figure 4D), and 20 (Figure 4F), while a shorter antinociceptive effect was produced by peptides 10 (Figure 4C) and 14 (Figure 4E) lasting about 2–3 h, still being longer than the effect of morphine. Compound 9 showed no dose-related antinociception and failed to reach a 50% effect after sc administration of 6 μmol/kg (Figure 4B). All peptides, except 9, were considerably more potent in eliciting an analgesic action than morphine (Figure 4 and Table 4).

In line with earlier reports,^{11,12,30} [Dmt¹]-DALDA 1 is a potent opioid antinociceptive agent when administered to mice sc in the tail-flick test, having a 44-fold increase in potency

relative to morphine and a prolonged duration of action (Figure 4A). The high potency that characterizes [Dmt¹]-DALDA 1, similarly to the ip administration, completely lost upon deletion of the Lys⁴ side chain amino group, resulting in analogue 9 (Figure 4B). On the contrary, compound 10 (Figure 4C), as well as its NMeLys⁴ analogue 14 (Figure 4E), induce a potent effect with a peak at 1 h. This observation clearly shows that only the removal of the Lys⁴ side chain functionality is detrimental for antinociception. Following sc administration, peptide 12, the *N*-methylated analogue of [Dmt¹]-DALDA 1, produced a prolonged antinociception action with a peak effect around 1–4 h and lasting up to 7 h (Figure 4D), a profile similar to that of the parent peptide. While it was equipotent to [Dmt¹]-DALDA, compound 12 was about 51-fold more potent than morphine (Table 4). This finding was also true when comparing peptide 10 and its *N*-methyl analogue 14, which shows comparable potencies and similar time course of antinociceptive action in mice after sc administration and an augmented potency relative to morphine. On this basis, *N*-methylation of the Lys residue in position 4 did not result in any major alterations in antinociceptive activities when injected sc, while its replacement with Nle has a detrimental effect. Compound 20 also produced a significant antinociceptive action after sc administration with a peak effect at 1 h (Figure 4F) but with a somewhat shorter duration of action than peptides 1 and 12. It was 3- and 4-fold less potent in eliciting an antinociceptive effect, respectively. However, compared to morphine, peptide 20 still shows 14-fold increased analgesic potency after sc administration. Exchanging the D-Arg² residue in peptides 1 and 12 with a D-Cit residue resulted in analogues 10 and 14, respectively, which retained high antinociceptive potency while having a shorter duration of action (Figure 4C,E).

Altogether, the new peptidic [Dmt¹]-DALDA analogues 10, 12, and 14 emerged as potent antinociceptive agents after ip and sc administration, with several-fold increased potency as compared to morphine. They differ in kinetic behavior, like BBB characteristics and tissue distribution, resulting in different kinetic profiles of the antinociceptive activity.

CONCLUSIONS

From the substitution of the residues of [Dmt¹]-DALDA at position 2 and 4, by structurally related, but uncharged amino acids (i.e., D-Arg² by D-Cit² and Lys⁴ by Nle⁴), we conclude that




Figure 4. Antinociceptive activities of peptides 1, 9, 10, 12, 14, and 20 and morphine after sc administration in the mouse tail-flick test. Dose- and time-dependent antinociceptive response presented as %MPE. Data are shown as mean \pm SEM.

side chain groups bearing the positive charges in [Dmt¹]-DALDA are not needed for efficient in vitro receptor binding and activation. However, the removal of either side chain charges did diminish the well-established MOR subtype

receptor selectivity of [Dmt¹]-DALDA. Enhanced DOR binding was observed when one charge and even more when the two charges were eliminated. This trend was conserved throughout the “parent” (1 and 9–11), the *N*-methylated (12–15) and the

Table 4. Antinociceptive Potencies of Peptides 1, 9, 10, 12, 14, and 20 in Comparison to Morphine after sc Administration in the Mouse Tail-Flick Test

compd	ED ₅₀ μmol/kg (95% confidence limits) ^a	relative potency to morphine
1	0.15 (0.07–0.32)	44
9	>6	nd
10	0.23 (0.10–0.55)	29
12	0.13 (0.06–0.30)	51
14	0.16 (0.07–0.36)	41
20	0.47 (0.18–1.2)	14
Morphine	6.6 (3.5–12.6)	1

^aED₅₀ was determined at the time of peak effect (i.e., 2 h for peptide 1 and 12, 1 h for peptides 10, 14, and 20, and 30 min for morphine). nd: not determined.

constrained “Aba” series (16–19). In regard to KOR affinity, the introduced modifications clearly had an impact on the binding affinity of the investigated peptides to this opioid receptor subtype. Low nanomolar KOR binding affinities were determined for peptide analogues 13, 14, 17, and 19 (with K_i^K values between 1.12 and 14.4 nM). Because of the liabilities related to μ opioid analgesics such as morphine, ligands of KOR have also received considerable attention as potential analgesics.³¹ In particular, KOR agonists have therapeutic potential in pain conditions associated with inflammation.

When looking at the transport properties of the peptide analogues in this study, all synthesized [Dmt¹]-DALDA peptides show influx into the brain parenchyma. The tissue distribution, on the other hand, indicated that the charged aminoalkyl chain of Lys⁴ and the guanidine moiety of D-Arg² are of significant importance for the biodistribution of the peptides. Deletion of these charges, via D-Arg²→D-Cit² and Lys⁴→Nle⁴ substitutions, decreases the 3+ net charge of the peptide, resulting in enhanced liver uptake and potentially influences brain accessibility. As shown in this work, subtle structural modifications can influence the biodistribution of the peptide analogues and could lead to a modulated peptide delivery to the CNS, thus affecting the ratio of centrally vs peripherally induced analgesia.

The ability of mice to sense a pain stimulus was verified after peripheral administration of a selection of opioid peptides. In contrast to the reference peptide [Dmt¹]DALDA 1, which showed a very potent analgesic effect, the low antinociceptive effect of peptide 9 could be rationalized by a limited brain intake after massive liver extraction. Peptide 20 showed a rapid brain influx but also a significant efflux, resulting in lower antinociception compared to the other peptides such as 1, 12, and 14.

Peptides 12 and 14 had the highest antinociceptive effect during the first 2 h of an ip injection, measured as AUC relative to morphine (normalized at 1 μmol/kg), followed by peptides 1 and 10. The presence of NMeLys⁴ at the carboxyl terminus of the peptide sequence is thus preferred for antinociceptive activity, followed by Lys⁴, while other amino acids like Gly⁴ and Nle⁴ significantly decreased the antinociception.

When the peptide analogues were investigated over a longer sc postinjection period (up to 7 h) in a dose-dependency study, it became apparent that two distinct antinociception profiles were obtained. Comparable ED₅₀ values were measured for peptides 1 and 12 (Dmt-D-Arg-Phe-(NMe)Lys-NH₂) in comparison with analogues 10 (H-Dmt-D-Cit-Phe-Lys-NH₂)

and 14 (Dmt-D-Cit-Phe-(NMe)Lys-NH₂), but the latter peptides produced their peak effect more rapidly (1 h vs 2 h postinjection for 1/12). The steep increase in potency was also accompanied by a rapid decrease after reaching the maximum in antinociceptive effect. These observations are interesting for the development of peptide-based pharmaceuticals aiming at different pain types. Peptide 10 could serve as a lead molecule for the treatment of acute (e.g., postoperative pain), whereas the long-lasting Dmt-D-Arg-Phe-NMeLys-NH₂ 12 could be useful for addressing chronic pain conditions (e.g., neuropathic pain). As the compounds investigated in this study are potent dual MOR/DOR (and even KOR, see 17) agonists, they could potentially be useful for the treatment of pain with reduced side effects and be effective at low administered doses.

EXPERIMENTAL SECTION

General. Thin layer chromatography (TLC) was performed on plastic sheet precoated with silica gel 60F₂₅₄ (Merck, Darmstadt, Germany) using specified solvent systems. Mass spectrometry (MS) was recorded on a Micromass Q-ToF Micro spectrometer using electrospray (ESP) ionization (positive or negative ion mode). Data collection was done with Masslynx software. Analytical reversed phase (RP)-HPLC was performed using an Agilent 1100 series system (Waldbronn, Germany) with a Supelco Discovery BIO Wide Pore (Bellefonte, PA, USA) RP C-18 column (25 cm × 4.6 mm, 5 μm) using UV detection at 215 nm. The mobile phase (water/acetonitrile) contained 0.1% TFA. The gradient consisted of a 20 min run from 3 to 97% acetonitrile at a flow rate of 1 mL/min. Preparative HPLC was performed on a Gilson apparatus and controlled with the software package Unipoint. The RP C18-column (Discovery BIO Wide Pore 25 cm × 21.2 mm, 10 μm) was used under the same conditions as the analytical RP-HPLC but with a flow rate of 20 mL min⁻¹. A purity of more than 95% was determined for all compounds by analytical RP-HPLC using the conditions described above. ¹H NMR and ¹³C NMR spectra were recorded at 250 and 63 MHz, respectively, on a Bruker Avance 250 spectrometer or at 500 and 125 MHz on a Bruker Avance II 500. Calibration was done with TMS (tetramethylsilane) or residual solvent signals as an internal standard. The solvent used is mentioned in all cases and the abbreviations used are: s (singlet), d (doublet), dd (double doublet), t (triplet), br s (broad singlet), and m (multiplet).

Opioid Receptor Binding Assays. Opioid receptor binding studies were performed as described in detail elsewhere.³⁵ Binding affinities for MOR and DOR were determined by displacing, respectively, [³H]DAMGO (Multiple Peptide Systems, San Diego, CA) and [³H]DSLET (Multiple Peptide Systems) from rat brain membrane binding sites, and KOR receptor affinities were measured by displacement of [³H]U69,593 (Amersham) from guinea pig brain membrane binding sites. Incubations were performed for 2 h at 0 °C with [³H]DAMGO, [³H]DSLET, and [³H]U69,593 at respective concentrations of 0.72, 0.78, and 0.80 nM. IC₅₀ values were determined from log-dose displacement curves, and K_i values were calculated from the IC₅₀ values by means of the equation of Cheng and Prusoff,³² using values of 1.3, 2.6, and 2.9 nM for the dissociation constants of [³H]DAMGO, [³H]DSLET, and [³H]U69,593, respectively.

Functional GPI and MVD Assays. The guinea pig ileum (GPI)³³ and mouse vas deferens (MVD)³⁴ bioassays were carried out as described in detail elsewhere.^{35,36} A dose–response curve was determined with [Leu⁵]enkephalin as standard for each ileum and vas preparation, and IC₅₀ values of the compounds being tested were normalized according to a published procedure.³⁷

Blood–Brain Barrier Transport. Animals. Male Institute for Cancer Research, caesarean derived-1 (ICR-CD-1) mice (Harlan Laboratories, Venray, The Netherlands), weighing 25–30 g, were used according to the Ethical Committee Principles of Laboratory Animal Welfare as approved by our institute (Ghent University, Faculty of Veterinary Medicine, 2009–052). Animals were housed under

standard laboratory conditions in a temperature and humidity regulated environment with food and water ad libitum.

Reagents and Peptides. Bovine serum albumin (BSA), calcium chloride dehydrate, D-glucose, HEPES, magnesium sulfate heptahydrate, potassium chloride, disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate monohydrate, sodium chloride, sodium lactate, urethane, and Krebs–Henseleit buffer were all purchased from Sigma (St. Louis, MO, USA) or Merck KGaA (Darmstadt, Germany). Dextran was obtained from AppliChem GmbH (Darmstadt, Germany), while dermorphin was purchased from Peptide Synthetics (PPR, Hampshire, United Kingdom). Morphine hydrochloride was acquired from Belgopia (Louvain-La-Neuve, Belgium).

Peptides ¹²⁵I Radiolabeling. The Dmt¹-DALDA peptides and controls (dermorphin and BSA) were labeled by the Iodogen method.^{37–39} Briefly, a 1 g/L peptide solution was prepared by dissolving about 1 mg in phosphate buffer (pH 7.4, 130 mM). An Iodo-Gen coated tube was previously rinsed with 1 mL of phosphate buffer. Subsequently, 50 μL of NaI (20 nmol/10 μL) and 10 μL of Na¹²⁵I solution (3700 MBq/ml) (Perkin-Elmer, Boston, MA, USA) were transferred into this Iodo-Gen coated tube. After 6 min of incubation at room temperature, the oxidation reaction of iodide to iodonium was stopped by removing the solution from the tube and adding the iodonium solution to a tube containing 50 μL of peptide solution (1 μg/μL). The iodination reaction of the peptide was allowed to proceed another 6 min at room temperature, after which the reaction mixture was purified with an Ag filter. After Ag purification, the radioactivity of the filtrate was measured using a dose calibrator (Veenstra, The Netherlands) to dilute the ¹²⁵I-peptide appropriately.

In addition, a quality control was performed on the filtrated peptide using a Vydac Everest C18 (250 mm × 4.6 mm ID, 300 Å, 5 μm particle size) HPLC column (Grace Vydac, Hesperia, CA, USA) in an oven set at 30 °C, with a mobile phase consisting of (A) 0.1% w/v formic acid in water and (B) 0.1% w/v formic acid in acetonitrile. A linear gradient was employed as follows:

Peptide 1: 0–50 min going from 98% to 50% A.

Peptides 9, 12, 14, and 20: 0–40 min going from 98% to 80% A.

Peptide 10: 0–40 min going from 98% to 60% A.

The flow rate was set at 1.0 mL/min with an injection volume of 100 μL.

The radio-HPLC apparatus consisted of a LaChrom Elite L-2130 pump with degasser, a LaChrom Elite L-2300 column oven, a LaChrom Elite L-2400 UV detector set at 215 nm (all Hitachi, Tokyo, Japan), a Rheodyne 7725i manual injector with 100 μL sample loop (Rheodyne, Rohnert Park, CA, USA), and a Berthold LB500 HERM radioactivity detector (Berthold Technologies, Bad Wildbad, Germany) equipped with EZChrom Elite version 3.1.7 software for data acquisition (Scientific Software, Pleasanton, CA, USA).

Multiple Time Regression (MTR). To determine whether the peptides could enter the brain, multiple time regression analysis was performed. The CD-1 mice were anesthetized with intraperitoneal (ip) urethane (3 g/kg), and the jugular vein and carotid artery were isolated. Then 200 μL of the radiolabeled peptides (30 000 cpm/μL) in lactated Ringer's (LR) solution containing 1% BSA were each injected separately into the jugular vein. At specified time points after injection, blood was obtained from the carotid artery and the mouse was decapitated. The brain was removed and weighed, after which radioactivity was determined in a gamma counter (Wallac Wizard automatic gamma counter, PerkinElmer, Shelton, CT, USA). The blood was centrifuged at 10000g for 15 min at 21 °C, and the radioactivity of the obtained serum was measured.

The theoretical background of the multiple time regression analysis is based on the Gjedde equation:²⁶

$$\frac{A_m(t)}{C_p(t)} = K_{in} \frac{\int_0^t C_p(t) dt}{C_p(t)} + V_i$$

where $A_m(t)$ is the amount of radioactivity in brain at time t , $C_p(t)$ the amount of radioactivity in serum at time t , K_{in} the brain influx rate constant, and V_i the initial brain distribution volume.

The exposure time ($\text{exp} \cdot t$) is defined as the integral of the serum radioactivity over time divided by the radioactivity at time t :

$$\text{exp} \cdot t = \frac{\int_0^t C_p(t) dt}{C_p(t)}$$

The integral of the radioactivity over time is represented by the area under the curve (AUC).

Finally, the brain/serum ratios (μL/g) were plotted versus exposure time. The initial slope of the linear portion of this relationship over the first minutes measured the unidirectional initial influx rate (K_{in} initial) from blood to brain. The intercept represents the brain volume of distribution (V_{br}).

As a system suitability controls of this method, BSA, the impermeable vascular marker, as well as dermorphin, a weak positive influx control peptide²⁸ were labeled with I-125 and their influx investigated as described above. In compliance with literature data,⁴⁰ a mean influx transfer constant of $0.0849 \pm 0.0847 \mu\text{L}/(\text{g} \times \text{min})$ was obtained for BSA, confirming negligible influx. The mean K_{in} over 15 min for dermorphin was $0.173 \pm 0.137 \mu\text{L}/(\text{g} \times \text{min})$, while the initial K_{in} was $5.52 \pm 1.41 \mu\text{L}/(\text{g} \times \text{min})$ if the first minutes are considered, justifying its choice as a weak positive brain influx control.

Capillary Depletion. This method was performed to determine to what extent the peptides, taken up by the brain, crossed the capillary wall instead of being trapped in the capillary cells. The method of Triguero et al.⁴¹ as modified by Gutierrez et al.⁴² was used. Summarizing, CD-1 mice were anesthetized with urethane (3 g/kg ip) and the jugular vein was isolated. Then 200 μL of the diluted peptide solution (10 000 cpm/μL) was injected in the jugular vein. At specified time points after injection, blood was collected from the abdominal aorta and the brain was perfused manually with 20 mL of LR buffer after severing the jugular veins. Subsequently, the brain was collected, homogenized with 0.7 mL of ice-cold capillary buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl₂, 1 mM MgSO₄, 1 mM NaH₂PO₄, and 10 mM D-glucose adjusted to pH 7.4) in a pyrex glass tube and mixed with 1.7 mL of 26% ice-cold dextran solution in capillary buffer. The resulting solution was weighed and centrifuged in a swinging bucket rotor (Eppendorf, Hamburg, Germany) at 5400g for 30 min at 4 °C. Pellet (capillaries) and supernatant (parenchyma and fat tissues) were collected, weighed, and measured in a gamma counter. After centrifuging the obtained blood, 50 μL of serum was collected and measured in a gamma counter. Compartmental BBB distribution was evaluated from plotting capillaries/serum and parenchyma/serum activity ratios versus time.

Brain to Blood Transport. This method was performed to quantify the amount of peptide pumped out of the brain by efflux transport.⁴³ CD-1 mice were anesthetized with urethane (3 g/kg ip), and the skin of the skull was removed. A hole was then made into the lateral ventricle, 1 mm lateral and 0.34 mm posterior to the bregma, with a 22 G needle carrying a tubing guard at a constant depth of 2 mm. The anesthetized mice received an intracerebroventricular (icv) injection of 1 μL of LR solution containing the labeled peptide (25000 cpm/μL) and 1% BSA at a speed of 360 μL/h for 10 s using a syringe pump (KDS100, KR analytical, Cheshire, UK). At specified time points after injection, blood was collected from the abdominal aorta and the mouse was decapitated. Subsequently, the whole brain was collected, weighed, and measured in a gamma counter. The efflux rate constant k_{out} (min⁻¹) was calculated from the linear regression of the natural logarithm of the residual radioactivity in brain versus time, applying first-order kinetics.

Tissue Distribution. Immediately after brain collection, spleen, liver, lungs, heart, and kidneys were collected.⁴⁴ Again, the tissues were weighed and measured in the gamma counter. For each tissue, the percentage of time-corrected injected dose (ID) was then calculated:

$$\text{Percentage ID(\%)} = \frac{\frac{A_{\text{tissue}}}{W_{\text{tissue}}}}{\frac{A_{\text{dose injected}}}{W_{\text{animal}}}} \times 100$$

where A_{tissue} is the radioactivity of the tissue, W_{tissue} the weight of the tissue, $A_{\text{dose injected}}$ the amount of radioactivity injected into the vein, and W_{animal} the body weight of the mouse.

In Vitro Metabolic Stability. To obtain information regarding the metabolic fate of peptides, the nonlabeled peptides were tested in vitro by incubating in mouse plasma and mouse brain homogenate.⁴⁵ In brief, 100 μg of the nonlabeled peptide dissolved in Krebs–Henseleit buffer (pH 7.4) was incubated in plasma or brain homogenate (250 μL of mouse plasma or 150 μg of tissue protein, respectively) at 37 °C while shaking. At suitable time points, aliquots were taken and immediately transferred into microtubes containing 10% v/v trifluoroacetic acid (TFA) solution in water to obtain a final concentration of 1:10 v/v solvent/aliquot. The samples were then heated for 5 min at 95 °C, followed by cooling in an ice-bath for 30 min. After centrifugation of the samples at 15000g for 15 min at 5 °C, the supernatants were analyzed using UPLC-PDA and HPLC-UV. Placebos (mouse plasma or tissue homogenate), controls (initially inactivated tissue proteases), and reference solutions (peptide dissolved in buffer) were similarly processed. The time-dependent decrease of the native peptide was quantified and from the linear regression between the quantified decrease and time, the half-life ($t_{1/2}$) was determined as:

$$t_{1/2} = \frac{\ln(2)}{k}$$

where k is the first-order rate constant.

If the calculated half-life was more than two times the experimental time, i.e., more than 4 h, no quantitative half-life was given and the results expressed as “stable”.

UPLC-PDA analyses were performed using Waters Acquity H-Class Biosamples FTN, a Waters Acquity H-Class BioQuaternary solvent manager, a Waters Acquity H-Class column module, and a Waters Acquity H-Class photodiode array detector (UV spectrum was recorded between 190 and 400 nm) equipped with Waters Empower Pro software version 2 (all Waters, Milford, MA, USA). Analysis was performed using a Waters Acquity UPLC BEH300 C18 column (100 mm \times 2.1 mm ID, 300 Å, 1.7 μm particle size) in an oven set at 35 °C. The following solvent system was used: (A) 10 mM ammonium carbonate and (B) acetonitrile. The gradient method consisted of a linear increase from 5% B to 60% B in 20 min, followed by 10 min reconditioning with initial composition 95/5 v/v A/B. The flow rate was set at 0.58 mL/min, and the injection volume was 5 μL .

The degradation of the peptides was also studied by use of an HPLC system consisting of a Waters Alliance 2695 separations module, a Waters column heater, and a Waters 2487 dual wavelength absorbance detector, fitted with Empower Pro software version 2 (all Waters, Milford, MA, USA). Quantification of the degradation was performed at 210 nm. Analysis was achieved using a Grace Alltech Prevail organic acid column (250 mm \times 4.6 mm I.D., 110 Å, 5 μm particle size) in an oven set at 30 °C, using (A) 25 mM phosphate buffer pH 8.0 and (B) acetonitrile. The following linear gradient method was used: from 10% B to 70% B in 45 min, followed by 15 min with the initial composition (90/10 v/v A/B) to recondition the system. The flow rate was set at 1.0 mL/min with an injection volume of 20 μL .

Antinociceptive Properties. *A. After ip Administration.* The same type of mice as used for the BBB transport studies were used in this assay. Antinociception was assessed using the 55 °C tail withdrawal method in CD-1 mice. Each mouse (10 mice per group) was first tested for consistency in baseline latency by immersing its tail in the water and recording the time to response. Mice were then administered the controls as well as the test compounds at a dose of 5 mg/kg body weight and tested for antinociception at various time points afterward. Antinociception was calculated as % antinociception or % MPE (percent maximum possible effect) using the following

formula: $100(\text{test latency} - \text{baseline latency}) / (10 - \text{baseline latency})$. To avoid tissue damage, a maximum score was assigned (100%) to animals that failed to respond within 10 s (= cutoff time).

A negative control consisted of a physiological 0.9% saline solution. Two positive controls were also included, i.e., morphine and demorphan, at a dose of 5 mg/kg. All controls were ip administered. The amount of antinociception was determined using the AUC:

$$\text{AUC} = \sum_{i=1}^n \left(\frac{y_i + y_{i-1}}{2} \times (x_i - x_{i-1}) \right)$$

within the 120 min time points, y the percentage of antinociception and x the time after injection (min). Assuming first-order kinetics, the AUC of the peptides and of morphine is converted to a theoretical AUC_p , respectively AUC_m , equivalent to a dose of 1 μmol active moiety/kg. The morphine normalized AUC for the peptides ($\text{AUC}_{\text{normalized}}$) is then calculated by:

$$\text{AUC}_{\text{normalized}} = \left(\frac{\text{AUC}_p}{\text{AUC}_m} \right) \times 100$$

B. After sc Administration. Male CD-1 mice (25–35 g) were purchased from Charles River Laboratories (Sulzfeld, Germany). Animals were housed under standard laboratory conditions in a temperature-regulated environment under a controlled 12 h light/dark cycle with food and water ad libitum. All animal procedures were approved by the Austrian Ethical Committee on Animal Care and Use in line with international laws and policies. Morphine hydrochloride was obtained from Gatt-Koller GmbH (Innsbruck, Austria). All drugs were dissolved in sterile physiological saline (0.9%) and were administered sc in a volume of 10 μL per 1 g body weight.

The radiant heat tail-flick test was used to assess antinociceptive effects of tested drugs after sc administration in mice using an UB 37360 Ugo Basile analgesiometer (Ugo Basile srl, Varese, Italy) as described.⁴⁶ The reaction time required by the mouse to move its tail due to the radiant heat was measured and defined as the tail-flick latency. A cutoff time of 10 s was also used in order to minimize tissue damage, and the % antinociception or MPE for each dose administered was calculated as above. At least three doses were tested, and five to six animals per dose were used. Antinociceptive ED_{50} values and 95% confidence limits were calculated by the method of Litchfield and Wilcoxon (1949).⁴⁷

Compound Synthesis and Characterization. Both Fmoc-Abalys-OH **8a** and Fmoc-Abalys-Nle-OH **8b** were prepared according to reported procedures (see Supporting Information).^{23,24} Subsequently, all peptides were assembled as mentioned before by standard SPPS protocols employing Fmoc- or Boc-protected amino acid residues or dipeptides (**8a** and **8b**).

Peptide Characterization. *H-Dmt-D-Arg-Phe-Lys-NH₂ (1).* HPLC (standard gradient): $t_{\text{ret}} = 8.46$ min. TLC R_f (EBAW), 0.50; TLC R_f (BAW), 0.24. ESI-HRMS [$M + H^+$]: $m/z = 640.3950$ (calculated for $\text{C}_{32}\text{H}_{48}\text{H}^+\text{N}_9\text{O}_5$: 640.3929).

H-Dmt-D-Arg-Phe-Nle-NH₂ (9). HPLC (standard gradient): $t_{\text{ret}} = 10.57$ min. TLC R_f (EBAW), 0.62; TLC R_f (BAW), 0.70. ESI-HRMS [$M + H^+$]: $m/z = 625.3793$ (calculated for $\text{C}_{32}\text{H}_{47}\text{H}^+\text{N}_8\text{O}_5$: 625.3820).

H-Dmt-D-Cit-Phe-Lys-NH₂ (10). HPLC (standard gradient): $t_{\text{ret}} = 8.68$ min. TLC R_f (EBAW), 0.52; TLC R_f (BAW), 0.35. ESI-HRMS [$M + H^+$]: $m/z = 641.3759$ (calculated for $\text{C}_{32}\text{H}_{47}\text{H}^+\text{N}_8\text{O}_6$: 641.3770).

H-Dmt-D-Cit-Phe-Nle-NH₂ (11). HPLC (standard gradient): $t_{\text{ret}} = 11.06$ min. TLC R_f (EBAW), 0.72; TLC R_f (BAW), 0.74. ESI-HRMS [$M + H^+$]: $m/z = 626.3651$ (calculated for $\text{C}_{32}\text{H}_{46}\text{H}^+\text{N}_7\text{O}_6$: 626.3661).

H-Dmt-D-Arg-Phe-NMeLys-NH₂ (12). HPLC (standard gradient): $t_{\text{ret}} = 8.43$ min. TLC R_f (EBAW), 0.52; TLC R_f (BAW), 0.24. ESI-HRMS [$M + H^+$]: $m/z = 654.4064$ (calculated for $\text{C}_{33}\text{H}_{50}\text{H}^+\text{N}_9\text{O}_5$: 654.4086).

H-Dmt-D-Arg-Phe-NMeNle-NH₂ (13). HPLC (standard gradient): $t_{\text{ret}} = 10.67$ min. TLC R_f (EBAW), 0.62; TLC R_f (BAW), 0.70. ESI-HRMS [$M + H^+$]: $m/z = 639.3983$ (calculated for $\text{C}_{33}\text{H}_{49}\text{H}^+\text{N}_8\text{O}_5$: 639.3977).

H-Dmt-D-Cit-Phe-NMELys-NH₂ (**14**). HPLC (standard gradient): $t_{\text{ret}} = 8.67$ min. TLC R_f (EBAW), 0.55; TLC R_f (BAW), 0.37. ESI-HRMS $[M + H]^+$: $m/z = 655.3915$ (calculated for $C_{33}H_{49}H^+N_8O_6$: 655.3929).

H-Dmt-D-Cit-Phe-NMeNle-NH₂ (**15**). HPLC (standard gradient): $t_{\text{ret}} = 11.81$ min. TLC R_f (EBAW), 0.72; TLC R_f (BAW), 0.74. ESI-HRMS $[M + H]^+$: $m/z = 640.3823$ (calculated for $C_{33}H_{48}H^+N_7O_6$: 640.3817).

H-Dmt-D-Arg-Aba-Lys-NH₂ (**16**). HPLC (standard gradient): $t_{\text{ret}} = 8.21$ min. TLC R_f (EBAW), 0.52; TLC R_f (BAW), 0.24. ESI-HRMS $[M + H]^+$: $m/z = 653.3913$ (calculated for $C_{33}H_{48}H^+N_9O_5$: 652.3929).

H-Dmt-D-Arg-Aba-Nle-NH₂ (**17**). HPLC (standard gradient): $t_{\text{ret}} = 11.25$ min. TLC R_f (EBAW), 0.75; TLC R_f (BAW), 0.74. ESI-HRMS $[M + H]^+$: $m/z = 637.3826$ (calculated for $C_{33}H_{47}H^+N_8O_5$: 637.3820).

H-Dmt-D-Cit-Aba-Lys-NH₂ (**18**). HPLC (standard gradient): $t_{\text{ret}} = 8.43$ min. TLC R_f (EBAW), 0.55; TLC R_f (BAW), 0.32. ESI-HRMS $[M + H]^+$: $m/z = 653.3794$ (calculated for $C_{33}H_{47}H^+N_8O_6$: 653.3770).

H-Dmt-D-Cit-Aba-Nle-NH₂ (**19**). HPLC (standard gradient): $t_{\text{ret}} = 11.57$ min. TLC R_f (EBAW), 0.77; TLC R_f (BAW), 0.74. ESI-HRMS $[M + H]^+$: $m/z = 638.3659$ (calculated for $C_{33}H_{46}H^+N_7O_6$: 638.3661).

H-Dmt-D-Arg-Aba-Gly-NH₂ (**20**). HPLC (standard gradient): $t_{\text{ret}} = 8.63$ min. TLC R_f (EBAW), 0.55; TLC R_f (BAW), 0.45. ESI-HRMS $[M + H]^+$: $m/z = 581.3220$ (calculated for $C_{29}H_{39}H^+N_8O_5$: 581.3195).

■ ASSOCIATED CONTENT

Supporting Information

Characterization of nonkey compounds, ED₅₀ values of selected peptides and morphine at different time points after sc administration, and Caco-2 cell permeability data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*For S.B.: phone, +32 2 6293292; E-mail: sballet@vub.ac.be. For B.D.S.: phone, +32 9 2648100; E-mail, bart.despiegeleer@ugent.be.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The work of S.B., D.T., and P.W.S. was supported by a collaboration convention between the Ministère du Développement Economique, de l'Innovation et de l'Exportation du Québec, and the Fund for Scientific Research—Flanders (FWO Vlaanderen) (PSR-SIIRI-417). S.V.D. thanks the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT—Vlaanderen) for a Ph.D. grant (no. 73402), and a Special Research Fund from the Ghent University (BOF) grant and mandate (no. 01J22510 and 01D38811) (E.W., B.D.S., S.S.). The research of P.W.S. was also supported by grants CIHR (MOP-89716), and the NIH (DA-004443). M.A.C. is supported by a NHMRC Australia Fellowship AF511105.

■ ABBREVIATIONS USED

Aba, 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one; AUC, area under the curve value; BBB, blood–brain barrier; BSA, bovine serum albumin; Cit, citrulline; CNS, central nervous system; DAMGO, $[D\text{-Ala}^2, N\text{MePhe}^4, \text{Gly-ol}^5]$ enkephalin; Dmt, 2',6'-dimethyl-(S)-tyrosine; DOR, δ -opioid receptor; DSLET, $[D\text{-Ser}^2, \text{Leu}^5]$ enkephalin-Thr⁶; ESP, electrospray ionization mass-spectrometry; GPI, guinea pig ileum; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HOBt, 1-hydroxybenzotriazole; ID, injected dose; ip, intraperitoneal; iv, intravenous; KOR, κ -opioid receptor; LR, lactated Ringer's

(solution); k_{out} , brain efflux rate coefficient; MOR, μ -opioid receptor; MPE, maximal possible effect; MTR, multiple time regression; MVD, mouse vas deferens; Nle, norleucine; NMM, N-methyl morpholine; K_{in} , unidirectional brain influx or uptake transfer constant; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; Phth, phthaloyl; RaNi, Raney nickel; SAR, structure–activity relationship; sc, subcutaneous; SEM, standard error of the mean; TBTU, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; V_{br} , brain distribution volume; Z, benzyloxycarbonyl

■ REFERENCES

- (1) Horan, P.; Tallarida, R. J.; Haaseth, R. C.; Matsunaga, T. O.; Hruby, V. J.; Porreca, F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. *Life Sci.* **1992**, *50*, 1535–1541.
- (2) He, L.; Lee, N. M. Delta Opioid Receptor Enhancement of Mu Opioid Receptor-Induced Antinociception in Spinal Cord. *J. Pharmacol. Exp. Ther.* **1998**, *285*, 1181–1186.
- (3) Coop, A.; Rice, K. C. Role of delta-opioid receptors in biological processes. *Drug News Perspect.* **2000**, *13*, 481–487.
- (4) Schiller, P. W.; Weltrowska, G.; Schmidt, R.; Nguyen, T. M. D.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C. Four different types of opioid peptides with mixed μ agonist/ δ antagonist properties. *Analgesia* **1995**, *1*, 703–706.
- (5) Purington, L. C.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. *J. Med. Chem.* **2009**, *52*, 7724–7731.
- (6) Purington, L. C.; Sobczyk-Kojiro, K.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Development and in vitro characterization of a novel bifunctional mu-agonist/delta-antagonist opioid tetrapeptide. *ACS Chem. Biol.* **2011**, *6*, 1375–1381.
- (7) For discussion and literature overview of MOR agonists/DOR antagonists: Schiller, P. W. Bi- or multi-functional opioid peptide drugs. *Life Sci.* **2010**, *86*, 598–603 and references therein.
- (8) Schiller, P. W.; Nguyen, T. M. D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. *Eur. J. Med. Chem.* **2000**, *35*, 895–901.
- (9) Szeto, H. H.; Lovelace, J. L.; Fridland, G.; Soong, Y.; Fasolo, J.; Wu, D.; Desiderio, D. M.; Schiller, P. W. In vivo pharmacokinetics of selective mu-opioid peptide agonists. *J. Pharmacol. Exp. Ther.* **2001**, *298*, 57–61.
- (10) Shimoyama, M.; Shimoyama, N.; Zhao, G. M.; Schiller, P. W.; Szeto, H. H. Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH₂ (DALDA) and $[Dmt^1]$ -DALDA. *J. Pharmacol. Exp. Ther.* **2001**, *297*, 364–371.
- (11) Neilan, C. L.; Nguyen, T. M. D.; Schiller, P. W.; Pasternak, G. W. Pharmacological characterization of the dermorphin analog $[Dmt^1]$ DALDA, a highly potent and selective mu-opioid peptide. *Eur. J. Pharmacol.* **2001**, *419*, 15–23.
- (12) Zhao, G. M.; Wu, D. L.; Soong, Y.; Shimoyama, M.; Berezowska, I.; Schiller, P. W.; Szeto, H. H. Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. *J. Pharmacol. Exp. Ther.* **2002**, *302*, 188–196.
- (13) Sagan, S.; Karoyan, P.; Lequin, O.; Chassaing, G.; Lavielle, S. N- and C-alpha methylation in biologically active peptides: synthesis, structural and functional aspects. *Curr. Med. Chem.* **2004**, *11*, 2799–2822.
- (14) (a) Toniolo, C.; Goodman, M. Introduction to the Synthesis of Peptidomimetic. In *Methods of Organic Chemistry: Synthesis of Peptides and Peptidomimetics* Goodman, M., Ed.; Thieme: Stuttgart, New York, 2003, Vol. E22c; (b) Hruby, V. J.; Li, G.; Haskell-Luevano, C.; Shenderovich, M. Design of peptides, proteins and peptidomimetics in Chi space. *Biopolymers* **1996**, *43*, 219–266. (c) Grauer, A.; König, B.

Peptidomimetics—A versatile Route to Biologically Active Compounds. *Eur. J. Org. Chem.* **2009**, 5099–5111.

(15) Ballet, S.; Feytens, D.; Buysse, K.; Chung, N. N.; Tumati, S.; Keresztes, A.; Van Duppen, J.; Lai, J.; Varga, F.; Porreca, F.; Schiller, P. W.; Vanden Broeck, J.; Tourwé, D. Design of Novel Neurokinin 1 Receptor Antagonists Based on Conformationally Constrained Aromatic Amino Acids and Discovery of a Potent Chimeric Opioid Agonist–Neurokinin 1 Receptor Antagonist. *J. Med. Chem.* **2011**, *54*, 2467–2476.

(16) Ballet, S.; Feytens, D.; De Wachter, R.; De Vlaeminck, M.; Marczak, E. D.; Salvadori, S.; de Graaf, C.; Rognan, D.; Negri, L.; Lattanzi, R.; Lazarus, L. H.; Tourwé, D.; Balboni, G. Conformationally Constrained Opioid Ligands: The Dmt-Aba and Dmt-Aia versus Dmt-Tic Scaffold. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 433–437.

(17) Tourwé, D.; Verschueren, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Toth, G.; Jaspers, H.; Verheyden, P.; Van Binst, G. Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology. *Biopolymers* **1996**, *38*, 1–12.

(18) Ballet, S.; Frycia, A.; Piron, J.; Chung, N. N.; Schiller, P. W.; Kosson, P.; Lipkowski, A. W.; Tourwé, D. Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH₂ using the 4-amino-2-benzazepin-3-one scaffold. *J. Pept. Res.* **2005**, *66*, 222–230.

(19) Guillemyn, K.; Kleczkowska, P.; Novoa, A.; Vandormael, B.; Van den Eynde, I.; Kosson, P.; Asim, M. F.; Schiller, P. W.; Spetea, M.; Lipkowski, A. W.; Tourwé, D.; Ballet, S. In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist–NK1 receptor antagonist chimera. *Mol. Brain* **2012**, *5*, 4.

(20) (a) Weltrowska, G.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Wilkes, B. C.; Schiller, P. W. N-Methylated cyclic analogues retain high opioid receptor binding affinity. *Chem. Biol. Drug. Des.* **2010**, *75*, 182–188. (b) Hansen, P. E.; Morgan, B. A. Structure–activity relationships in enkephalin peptides. In *The Peptides: Analysis, Synthesis, Biology*, Vol. 6: *Opioid Peptides: Biology, Chemistry and Genetics*; Udenfriend, S., Meienhofer, J., Eds.; Academic Press: Orlando, FL, 1984; pp 269–321.

(21) Ballet, S.; Misicka, A.; Kosson, P.; Lemieux, C.; Chung, N. N.; Schiller, P. W.; Lipkowski, A. W.; Tourwé, D. Dermorphin Tetrapeptide Analogues: Role of Lipophilicity vs Structural Flexibility. *J. Med. Chem.* **2008**, *51*, 2571–2574.

(22) B. Vandormael, B.; Fourla, D.-D.; Gramowski-Vaz, A.; Kosson, P.; Weiss, D. G.; Schröder, O. H.-U.; Lipkowski, A. W.; Georgoussi, Z.; Tourwé, D. Superpotent [Dmt1]Dermorphin Tetrapeptides Containing the 4-Aminotetrahydro-2-benzazepin-3-one Scaffold with Mixed m/d Opioid Receptor Agonistic Properties. *J. Med. Chem.* **2011**, *54*, 7848–7859.

(23) Van Rompaey, K.; Van den Eynde, I.; De Kimpe, N.; Tourwé, D. A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones. *Tetrahedron* **2003**, *59*, 4421–4432.

(24) Ballet, S.; Mayorov, A.; Cai, M.; Tymecka, D.; Chandler, K. B.; Palmer, E. S.; Van Rompaey, M.; Misicka, A.; Tourwé, D.; Hruby, V. J. Novel selective human melanocortin-3 receptor ligands: Use of the 4-amino-1,2,4,5-tetrahydro-benzazepin-3-one (Aba) scaffold. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2492–2498.

(25) Casimir, J. R.; Guichard, G.; Briand, J. P. Methyl 2-((succinimidooxy)carbonyl)benzoate (MSB): a new, efficient reagent for N-phthaloylation of amino acid and peptide derivatives. *J. Org. Chem.* **2002**, *67*, 3764–3768.

(26) Gjedde, A. High-affinity and low-affinity transport of D-glucose from blood to brain. *J. Neurochem.* **1981**, *36*, 1463–1471.

(27) Van Dorpe, S.; Adriaens, A.; Polis, I.; Peremans, K.; Van Bocxlaer, J.; De Spiegeleer, B. Analytical characterization and comparison of the blood–brain barrier permeability of eight opioid peptides. *Peptides* **2010**, *31*, 1390–1399.

(28) Van Dorpe, S.; Adriaens, A.; Vermeire, S.; Polis, I.; Peremans, K.; De Spiegeleer, B. Desirability function combining metabolic stability and functionality of peptides. *J. Pept. Sci.* **2011**, *17*, 398–404.

(29) Van Dorpe, S.; Bronselaer, A.; Nielandt, J.; Stalmans, S.; Wynendaele, E.; Audenaert, K.; Van De Wiele, C.; Burvenich, C.; Peremans, K.; Hsueh, H.; De Tré, G.; De Spiegeleer, B. Brainpeps: the blood–brain barrier peptide database. *Brain Struct. Funct.* **2012**, DOI: 10.1007/s00429-011-0375-0.

(30) Riba, P.; Ben, Y.; Nguyen, T. M. D.; Furst, S.; Schiller, P. W.; Lee, N. M. [Dmt¹]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine. *Curr. Med. Chem.* **2002**, *9*, 31–39.

(31) Aldrich, J. V.; McLaughlin, J. P. Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. *AAPS J.* **2009**, *11*, 312–322.

(32) Cheng, Y. C.; Prusoff, W. H. Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor Which Causes 50% (I_{50}) of an Enzymatic Reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099–3108.

(33) Paton, W. D. M. The Action of Morphine and Related Substances on Contraction and on Acetylcholine Output of Coaxially Stimulated Guinea Pig Ileum. *Br. J. Pharmacol. Chemother.* **1957**, *12*, 119–127.

(34) Henderson, G.; Hughes, J.; Kosterlitz, H. W. A New Example of a Morphine-Sensitive Neuro-Effector Junction: Adrenergic Transmission in the Mouse Vas Deferens. *Br. J. Pharmacol.* **1972**, *46*, 764–766.

(35) Schiller, P. W.; Lipton, A.; Horrobin, D. F.; Bodansky, M. Unsulfated C-Terminal 7-Peptide of Cholecystokinin: A New Ligand of the Opiate Receptor. *Biochem. Biophys. Res. Commun.* **1978**, *85*, 1332–1338.

(36) DiMaio, J.; Nguyen, T. M. D.; Lemieux, C.; Schiller, P. W. Synthesis and Pharmacological Characterization in Vitro of Cyclic Enkephalin Analogues: Effect of the Conformational Constraints on Opioid Receptor Selectivity. *J. Med. Chem.* **1982**, *25*, 1432–1438.

(37) Waterfield, A. A.; Leslie, F. M.; Lord, J. A. H.; Ling, N.; Kosterlitz, H. W. Opioid Activities of Fragments of β -Endorphin and Its Leucine⁵-Analogue. Comparison of the Binding Properties of Methionine- and Leucine-Enkephalin. *Eur. J. Pharmacol.* **1979**, *58*, 11–18.

(38) Vergote, V.; Baert, B.; Vandermeulen, E.; Peremans, K.; Van Bree, H.; Slegers, G.; Burvenich, C.; De Spiegeleer, B. LC-UV/MS characterisation and DOE optimization of the iodinated peptide obestatin. *J. Pharm. Biomed. Anal.* **2008**, *46*, 127–136.

(39) Vergote, V.; Bode, S.; Peremans, K.; Van Bree, H.; Baert, B.; Slegers, G.; Burvenich, C.; De Spiegeleer, B. Analysis of iodinated peptides by LC-DAD/ESI ion trap mass spectrometry. *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.* **2007**, *850*, 213–220.

(40) Kastin, A. J.; Akerstrom, V. Entry of exendin-4 into brain is rapid but may be limited at high doses. *Int. J. Obes.* **2003**, *27*, 313–318.

(41) Triguero, D.; Buciak, J.; Pardridge, W. M. Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. *J. Neurochem.* **1990**, *54*, 1882–1888.

(42) Gutierrez, E. G.; Banks, W. A.; Kastin, A. J. Murine tumor necrosis factor-alpha is transported from blood to brain in the mouse. *J. Neuroimmunol.* **1993**, *47*, 169–176.

(43) Banks, W. A.; Kastin, A. J.; Conn, P. M. Quantifying carrier-mediated transport of peptides from the brain to the blood. In *Methods in Enzymology*; Academic Press: New York, 1989; Vol. 168, pp 652–660.

(44) Czihal, P.; Knappe, D.; Fritsche, S.; Zahn, M.; Berthold, N.; Piantavigna, S.; Müller, U.; Van Dorpe, S.; Herth, N.; Binas, A.; Köhler, G.; De Spiegeleer, B.; Martin, L. L.; Nolte, O.; Sträter, N.; Alber, G.; Hoffman, R. Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens. *ACS Chem. Biol.* **2012**, *7*, 1281–1291.

(45) Svenson, J.; Vergote, V.; Karstad, R.; Burvenich, C.; Svendsen, J. S.; De Spiegeleer, B. Metabolic Fate of Lactoferricin-Based Antimicrobial Peptides: Effect of Truncation and Incorporation of Amino Acid Analogs on the In Vitro Metabolic Stability. *J. Pharmacol. Exp. Ther.* **2010**, *332*, 1032–1039.

(46) Spetea, M.; Bohotin, C. R.; Asim, M. F.; Stüebegger, K.; Schmidhammer, H. In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel μ opioid analgesic with reduced propensity to alter motor function. *Eur. J. Pharm. Sci.* **2010**, *41*, 125–135.

(47) Litchfield, J. T., Jr.; Wilcoxon, F. A simplified method of evaluating dose–effect experiments. *J. Pharmacol. Exp. Ther.* **1949**, *96*, 99–113.